Clinical evaluation of immunotherapy: are there differences between papillary and flat in situ bladder cancer?
The advantage of BCG immunotherapy over intravesical chemotherapy in superficial bladder cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50% to more than 70% and the proportion of patients remaining disease free for 5 years is increased from 20% to 40%. Similar advantages have been reported using suboptimal BCG treatment schedules in patients with recurrent stage Ta, T1 tumours. BCG provides long term protection from tumour recurrence and, unlike chemotherapy, reduces tumour progression. The observed relative increased sensitivity of CIS to BCG and the occasional failure of BCG to demonstrate significant superiority over mitomycin C in the prevention of tumour appear to be related to the use of suboptimal BCG treatment schedules. With maintenance BCG using 3 weekly instillations at 6 month intervals, patients with papillary tumours fare even better than patients with CIS, and tumour progressio is even further reduceld. Chemotherapy is appropriate for patients who are at very low risk of tumour progression and those who fail to respond to BCG, but overall the results of BCG immunotherapy are superior for patients with either CIS or Ta, T1 transitional cell carcinoma.
Lamm
D L
DL
Department of Urology, Robert C. Byrd Health Sciences Center of West Virginia University, Morgantown, West Virginia, USA.
D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000627:therapeutic use; D002278:Carcinoma in Situ / Q000628:therapy*; D002291:Carcinoma, Papillary / Q000628:therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D001500:BCG Vaccine